Brian J. Brazeau
Cargill
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Brian J. Brazeau.
Biochemistry | 2008
Nataša Mitić; Jennifer K. Schwartz; Brian J. Brazeau; John D. Lipscomb; Edward I. Solomon
The multicomponent soluble form of methane monooxygenase (sMMO) catalyzes the oxidation of methane through the activation of O 2 at a nonheme biferrous center in the hydroxylase component, MMOH. Reactivity is limited without binding of the sMMO effector protein, MMOB. Past studies show that mutations of specific MMOB surface residues cause large changes in the rates of individual steps in the MMOH reaction cycle. To define the structural and mechanistic bases for these observations, CD, MCD, and VTVH MCD spectroscopies coupled with ligand-field (LF) calculations are used to elucidate changes occurring near and at the MMOH biferrous cluster upon binding of MMOB and the MMOB variants. Perturbations to both the CD and MCD are observed upon binding wild-type MMOB and the MMOB variant that similarly increases O 2 reactivity. MMOB variants that do not greatly increase O 2 reactivity fail to cause one or both of these changes. LF calculations indicate that reorientation of the terminal glutamate on Fe2 reproduces the spectral perturbations in MCD. Although this structural change allows O 2 to bridge the diiron site and shifts the redox active orbitals for good overlap, it is not sufficient for enhanced O 2 reactivity of the enzyme. Binding of the T111Y-MMOB variant to MMOH induces the MCD, but not CD changes, and causes only a small increase in reactivity. Thus, both the geometric rearrangement at Fe2 (observed in MCD) coupled with a more global conformational change that may control O 2 access (probed by CD), induced by MMOB binding, are critical factors in the reactivity of sMMO.
Applied and Environmental Microbiology | 2006
Brian J. Brazeau; Steven J. Gort; Holly Jessen; Amy J. Andrew; Hans H. Liao
ABSTRACT The development of lysine 2,3-aminomutase as a robust biocatalyst hinges on the development of an in vivo activation system to trigger catalysis. This is the first report to show that, in the absence of chemical reductants, lysine 2,3-aminomutase activity is dependent upon the presence of flavodoxin, ferredoxin, or flavodoxin-NADP+ reductase.
Biochemistry | 2000
Brian J. Brazeau; John D. Lipscomb
Journal of the American Chemical Society | 2001
Brian J. Brazeau; Rachel N. Austin; Carly Tarr; John T. Groves; John D. Lipscomb
Biochemistry | 2003
Brian J. Brazeau; John D. Lipscomb
Archive | 2006
Brian J. Brazeau; Mervyn L. De Souza; Steven J. Gort; Paula M. Hicks; Sherry R. Kollmann; Jose Laplaza; Sara C. Mcfarlan; Fernando A. Sanchez-Riera; Christopher Solheid
Archive | 2010
Todd Banner; John Andrew Bohlmann; Brian J. Brazeau; Tzyy-Jan Han; Paul Loucks; Shannon Shriver; Shuang Zhou
Archive | 2006
Ravi R. Gokarn; Steven J. Gort; Holly Jessen; Hans H. Liao; Brian J. Brazeau
Archive | 2005
Brian J. Brazeau; Troostembergh Jean-Claude De; Paula M. Hicks; Holly Jessen; Sara C. Mcfarlan; Willy Richard Obyn; Fernando A. Sanchez-Riera; William A. Schroeder
Archive | 2007
Brian J. Brazeau; Yong-Uk Shin; Hye-Won Um; Jin-Sook Chang; Kwang Myung Cho; Young Wook Cho; Mervyn L. Desouza; Holly Jessen; So Young Kim; Wei Niu; Fernando A. Sanchez-Riera